Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2007
进行中（未招募）
1
16.7%
已完成
1
16.7%
招募中
3
50.0%
撤回
1
16.7%
暂无批准数据
- Bio-Path Holdings reported clinical progress across its cancer drug pipeline, with two AML patients demonstrating continued treatment durability after receiving over 15 treatment cycles and remaining in complete remission. - The company's BP1001-A solid tumor trial showed a patient experiencing a 15% reduction in primary tumor through ten cycles of treatment after failing extensive chemotherapy and surgical treatment for gynecologic cancer. - Bio-Path's BP1002 trial for venetoclax-resistant AML patients completed dose escalation to 60 mg/m2 without dose-limiting toxicities, with enrollment closing faster than expected due to high patient need. - The company is expanding its pipeline to include obesity treatment for Type 2 diabetes patients, with preclinical studies showing BP1001-A's potential to improve insulin sensitivity and prevent insulin resistance.
- Bio-Path Holdings has secured $4 million in private placement to bolster its financial position for advancing clinical trials of its cancer treatments. - Prexigebersen, Bio-Path's lead candidate, has completed Phase 1 trials for AML and is in Phase 2 trials, with potential applications in obesity-related cancers. - BP1001-A, an enhanced version of prexigebersen, has begun Phase 1 trials for solid tumors, demonstrating a favorable safety profile in higher dose cohorts. - BP1003 is in pre-clinical development for pancreatic cancer, showing success in penetrating pancreatic tumors, highlighting Bio-Path's commitment to addressing multiple cancer types.
- Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers. - A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months. - Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle. - Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.
- Bio-Path Holdings initiated a therapeutic program, BP1001-A, for obesity and related metabolic diseases, marking the first non-cancer application of its DNAbilize® technology. - The company completed enrollment for the third dosing cohort of its Phase 1/1b clinical trial of BP1002 in venetoclax-resistant AML patients, ahead of schedule. - A publication in Biomedicines highlighted the broad anti-tumor effect of BP1003 in preclinical solid tumor models, including breast, ovarian, and pancreatic cancer. - Bio-Path reported a positive response in a solid tumor patient in the BP1001-A Phase 1/1b trial, suggesting potential as a treatment for advanced solid tumors.
- Bio-Path Holdings announces a publication in _Biomedicines_ highlighting BP1003's therapeutic potential across various cancer types. - BP1003, a STAT3 mRNA-targeting antisense drug, showed broad anti-tumor effects in preclinical models of breast, ovarian, and pancreatic cancer. - The study suggests BP1003 could enhance the efficacy of standard chemotherapies in treating difficult-to-treat cancers by targeting STAT3. - Bio-Path plans to file an IND application for BP1003, furthering its development as a specific STAT3 inhibitor.
